Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment or prepayment of borrowings
-
Funding long term working capital requirements
-
Inorganic growth through acquisitions
-
General corporate purposes
-
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Entero Healthcare Solutions Limited is a healthcare products distribution company based in India, incorporated in 2018. The company operates a technology enabled platform that connects pharmaceutical and healthcare product manufacturers with pharmacies, hospitals and clinics across the country, handling procurement, warehousing and last mile delivery of medicines and other healthcare products. By the close of fiscal year 2023, the company's distribution network spanned 73 warehouses across 37 cities in 19 states and union territories, reaching customers in 495 districts. It served more than 81,400 pharmacy customers and around 3,400 hospitals, sourcing from over 1,900 manufacturer relationships and offering a catalogue of more than 64,500 product SKUs, supported by a workforce of roughly 3,000 employees. The company has positioned itself among the top three healthcare products distributors in India by revenue as of fiscal 2022, competing in a highly fragmented pharmaceutical distribution industry. Its growth strategy has combined organic expansion of its distribution footprint with acquisitions of regional distributors, aimed at consolidating market share and improving supply chain efficiency across the healthcare retail ecosystem.
Ahead of the issue, the company raised approximately Rs 716 crore from anchor investors at Rs 1,258 per share, with participation from marquee names including Smallcap World Fund, the Government of Singapore, the Monetary Authority of Singapore, Carmignac Portfolio, CLSA, Societe Generale, Morgan Stanley, Goldman Sachs, Amundi Funds and Jupiter India Fund, among others.
Source: RHP • Analysis provided for informational purposes
Last Updated: 17 July 2026, 5:30 AM
Leading distribution scale
The company ranks among the top three healthcare products distributors in India by revenue, giving it negotiating leverage with manufacturers and broad reach across pharmacies and hospitals.
Negative operating cash flows
The company has reported negative cash flows from operating, investing and financing activities in past periods, which could constrain its ability to fund operations and growth without external capital.
Acquisition integration risk
Growth through acquisitions carries the risk that expected synergies and benefits from past or future deals may not be fully realized, which could affect profitability.
Entero Healthcare Solutions Limited
Plot No. I-35, Building-B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.